Table 7—

Association of matrix metalloproteinase(MMP) single nucleotide polymorphisms and progression free survival (PFS) or overall survival (OS)

PolymorphismGenotypesPatients nPFSOS
All (n = 349)SCLC (n = 161)NSCLC (n = 187)Etoposide (n = 157)Gemcitabine (n = 143)All (n = 349)SCLC (n = 161)NSCLC (n = 187)Etoposide (n = 157)Gemcitabine (n = 143)
MMP1
 1G-16072GG/G961 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
G/GG+2530.7 (0.6–1.0)#0.7 (0.5–1.1)0.7 (0.5–1.0)0.7 (0.5–1.1)0.7 (0.4–1.1)0.9 (0.7–1.2)0.7 (0.5–1.1)0.9 (0.6–1.4)0.8 (0.5–1.2)0.9 (0.6–1.5)
GG/GG
MMP2
 C-735TCC2661 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
CT+TT811.0 (0.8–1.4)0.9 (0.6–1.4)1.1 (0.7–1.6)0.9 (0.6–1.4)1.1 (0.6–1.7)1.0 (0.8–1.4)0.9 (0.6–1.5)1.1 (0.7–1.7)1.0 (0.6–1.5)0.9 (0.5–1.6)
MMP36A 6A901 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
 6A-1171 5A6A 5A+5A 5A2590.9 (0.7–1.3)1.2 (0.8–1.7)0.8 (0.6–1.3)1.2 (0.8–1.8)0.9 (0.5–1.4)0.9 (0.7–1.3)1.1 (0.7–1.8)0.8 (0.5–1.3)1.2 (0.8–1.9)0.7 (0.4–1.2)
MMP7
 C-153TCC2871 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
CT+TT601.0 (0.7–1.4)1.4 (0.9–2.3)0.8 (0.5–1.2)1.5 (0.9–2.4)0.8 (0.4–1.3)1.0 (0.7–1.5)1.2 (0.7–2.0)0.8 (0.5–1.4)1.2 (0.7–2.1)1.0 (0.5–1.8)
 A-181GAA661 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
AG+GG2830.9 (0.7–1.2)0.7 (0.5–1.1)1.0 (0.6–1.5)0.7 (0.5–1.1)0.9 (0.6–1.4)1.0 (0.7–1.4)0.6 (0.3–1.0)1.3 (0.8–2.2)0.6 (0.4–1.0)1.3 (0.8–2.3)
MMP9
 C-1562TCC2611 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
CT+TT871.2 (0.9–1.6)1.3 (0.9–2.0)1.1 (0.8–1.7)1.4 (0.9–2.0)0.9 (0.6–1.4)1.1 (0.8–1.6)1.2 (0.8–2.0)1.1 (0.7–1.7)1.2 (0.8–2.0)1.0 (0.6–1.7)
MMP12
 A-82GAA2541 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
AG+GG940.9 (0.7–1.2)0.7 (0.5–1.1)1.1 (0.7–1.6)0.7 (0.5.1.0)1.0 (0.7–1.6)0.7 (0.5–1.0)0.5 (0.3–0.8)+1.1 (0.7–1.7)0.5 (0.3–0.8)1.1 (0.7–1.8)
 A1082GAA3081 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
AG+GG401.3 (0.9–1.9)1.4 (0.8–2.3)1.3 (0.7–2.3)1.4 (0.8–2.4)1.9 (1.0–3.5)§1.4 (0.9–2.0)1.5 (0.9–2.7)1.3 (0.7–2.3)1.5 (0.9–2.7)1.8 (0.9–3.5)
  • Data are presented as hazards ratio (95% CI), unless otherwise stated. All results for PFS were adjusted for stage. For OS, additional adjustment for sex was conducted. SCLC: small cell lung cancer; NSCLC: nonsmall cell lung cancer. Bold indicates significance. #: p = 0.04; : p = 0.05; +: p = 0.0026; §: p = 0.04.